HAC (Russian)
RSCI (Russian)
Ulrichsweb (Ulrich’s Periodicals Directory)
Scientific Indexing Services


DOI: https://doi.org/10.29296/25877305-2018-05-05
Download full text PDF

I. Gladyshev; O. Papsuev, Candidate of Medical Sciences Moscow Research Institute of Psychiatry, Branch, V.P. Serbsky National Medical Research Center of Psychiatry and Narcology, Ministry of Health of Russia

Affective and anxiety disorders are often accompanied by chronic pain syndrome. These can be both headache or back pain and abdominal pain, heart or joint pain. These conditions are frequently difficult to diagnose and treat in the primary healthcare network because they are not directly associated with mental disorder. Traditionally, tricyclic antidepressants have been used to treat chronic pain syndrome that is associated with both mental pathology and somatic diseases. However, there are currently available selective serotonin and noradrenaline reuptake inhibitors, such as venlafaxine that has proven its efficacy and safety in the therapy of chronic pain syndrome.

venlafaxine organica
chronic pain
neuropathic pain

It appears your Web browser is not configured to display PDF files. Download adobe Acrobat или click here to download the PDF file.

  1. Baron R. Mechanisms of disease: neuropathic pain – a clinical perspective // Nat. Clin. Pract. Neurol. – 2006; 2: 95–106.
  2. Lai J., Hunter J., Porreca F. The role of voltage-gated sodium channels in neuropathic pain // Curr. Opin. Neurobiol. – 2003; 13: 291–7.
  3. Bahia P., Suzuki R., Benton D. et al. A functional role for small-conductance calcium-activated potassium channels in sensory pathways including nociceptive processes // J. Neurosci. – 2005; 25: 3489–98.
  4. Dib-Hajj S., Black J., Waxman S. Voltage-gated sodium channels: therapeutic targets for pain // Pain Med. – 2009; 10: 1260–9.
  5. Ducreux D., Attal N., Parker F. et al. Mechanisms of central neuropathic pain: a combined psychophysical and fMRI study in syringomyelia // Brain. – 2006; 128: 963–76.
  6. Danilov A.B., Davydov O.S. Nejropaticheskaja bol' / M.: Borges, 2007.
  7. Edwards R., Giles J., Bingham C. 3rd. et al. Moderators of the negative effects of catastrophizing in arthritis // Pain Med. – 2010; 11: 591–9.
  8. Bouhassira D., Lanteri-Minet M., Attal N. et al. Prevalence of chronic pain with neuropathic characteristics in the general population // Pain. – 2008; 136: 380–7.
  9. Smith B., Torrance N. Epidemiology of neuropathic pain and its impact on quality of life // Curr. Pain Headache Rep. – 2012; 16: 191–8.
  10. Radat F., Margot-Duclot A., Attal N. Psychiatric co-morbidities in patients with chronic peripheral neuropathic pain: a multicentre cohort study // Eur. J. Pain. – 2013; 17 (10): 1547–57.
  11. Cohen S., Mao J. Neuropathic pain: Mechanisms and their clinical implications // BMJ. – 2014; 348: f7656.
  12. Gold Standard, Inc. Venlafaxine. Clinical Pharmacology [database online]. http://www.clinical pharmacology.com (accessed 20 April 2016).
  13. Aiyer R. et al. Treatment of Neuropathic Pain with Venlafaxine: A Systematic Review // Pain Med. – 2017; 18 (10): 1999–2012. DOI: 10.1093/pm/pnw261.
  14. Wang S., Howell S., Scatina J. et al. The disposition of venlafaxine enantomers in dogs, rats, and humans receiving venlafaxine // Chiralily. – 1992; 4: 84–90.
  15. Holliday S., Benfield P. Venlafaxine. A review of its pharmacology and therapeutic potential in depression // Drugs. – 1995; 49 (2): 280–94.
  16. Preskorn S. Pharmacotherapeutic profile of venlafaxine // Eur. Psychiatry. – 1997; 12 (Suppl. 4): 285–94.
  17. Sansone R., Sansone L. Pain, pain, go away // Psychiatry (Edgmont). – 2008; 5 (12): 16–9.
  18. Yucel A., Ozyalcin S., Koknel Talu G. et al. The effect of venlafaxine on ongoing and experimentally induced pain in neuropathic pain patients: A double blind, placebo controlled study // Eur. J. Pain. – 2005; 9 (4): 407–16.
  19. Dworkin R., O’Connor A., Audette J. et al. Recommendations for the pharmacological management of neuropathic pain: An overview and literature update // Mayo Clin. Proc. – 2010; 85 (3 suppl.): 3–14.
  20. Trouvin A. et al. Efficacy of Venlafaxine in Neuropathic Pain: A Narrative Review of Optimized Treatment // Clin. Ther. – 2017; 39 (6): 1104–22.
  21. Gladyshev I.O., Borodulina E.V., Papsuev O.O. Selektivnyj ingibitor obratnogo zahvata serotonina i noradrenalina Venlafaksin Organika: rezul'taty issledovanija bioekvivalentnosti // Sots. i klin. psihiat. – 2017; 27 (3): 86–93.